Source:http://linkedlifedata.com/resource/pubmed/id/21690560
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
7
|
| pubmed:dateCreated |
2011-8-19
|
| pubmed:abstractText |
Allogeneic hematopoietic cell transplantation in multiple myeloma is limited by prior reports of high treatment-related mortality. We analyzed outcomes after allogeneic hematopoietic cell transplantation for multiple myeloma in 1207 recipients in 3 cohorts based on the year of transplantation: 1989-1994 (n = 343), 1995-2000 (n = 376), and 2001-2005 (n = 488). The most recent cohort was significantly older (53% > 50 years) and had more recipients after prior autotransplantation. Use of unrelated donors, reduced-intensity conditioning and the blood cell grafts increased over time. Rates of acute graft-versus-host (GVHD) were similar, but chronic GVHD rates were highest in the most recent cohort. Overall survival (OS) at 1-year increased over time, reflecting a decrease in treatment-related mortality, but 5-year relapse rates increased from 39% (95% confidence interval [CI], 33%-44%) in 1989-1994 to 58% (95% CI, 51%-64%; P < .001) in the 2001-2005 cohort. Projected 5-year progression-free survival and OS are 14% (95% CI, 9%-20%) and 29% (95% CI, 23%-35%), respectively, in the latest cohort. Increasing age, longer interval from diagnosis to transplantation, and unrelated donor grafts adversely affected OS in multivariate analysis. Survival at 5 years for subjects with none, 1, 2, or 3 of these risk factors were 41% (range, 36%-47%), 32% (range, 27%-37%), 25% (range, 19%-31%), and 3% (range, 0%-11%), respectively (P < .0001).
|
| pubmed:grant | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Aug
|
| pubmed:issn |
1528-0020
|
| pubmed:author |
pubmed-author:CallanderNatalie SNS,
pubmed-author:DispenzieriAngelaA,
pubmed-author:FreytesCésar OCO,
pubmed-author:GaleRobert PeterRP,
pubmed-author:HamadaniMehdiM,
pubmed-author:HariParameswaran NPN,
pubmed-author:KambleRammurti TRT,
pubmed-author:KrishnanAmritaA,
pubmed-author:KumarShajiS,
pubmed-author:KyleRobert ARA,
pubmed-author:LazarusHillard MHM,
pubmed-author:LiPeigangP,
pubmed-author:LillMichaelM,
pubmed-author:LonialSagarS,
pubmed-author:MaiolinoAngeloA,
pubmed-author:MajhailNavneet SNS,
pubmed-author:MeehanKenneth RKR,
pubmed-author:MiloneGustavo AGA,
pubmed-author:NathRajneeshR,
pubmed-author:VesoleDavid HDH,
pubmed-author:VijRaviR,
pubmed-author:VoglDan TDT,
pubmed-author:WeissBrendanB,
pubmed-author:WiernikPeter HPH,
pubmed-author:WirkBaldeepB,
pubmed-author:ZhangMei-JieMJ
|
| pubmed:issnType |
Electronic
|
| pubmed:day |
18
|
| pubmed:volume |
118
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1979-88
|
| pubmed:meshHeading |
pubmed-meshheading:21690560-Adult,
pubmed-meshheading:21690560-Aged,
pubmed-meshheading:21690560-Cohort Studies,
pubmed-meshheading:21690560-Female,
pubmed-meshheading:21690560-Graft vs Host Disease,
pubmed-meshheading:21690560-Humans,
pubmed-meshheading:21690560-Male,
pubmed-meshheading:21690560-Middle Aged,
pubmed-meshheading:21690560-Multiple Myeloma,
pubmed-meshheading:21690560-Stem Cell Transplantation,
pubmed-meshheading:21690560-Survival Analysis,
pubmed-meshheading:21690560-Transplantation, Homologous,
pubmed-meshheading:21690560-Treatment Outcome,
pubmed-meshheading:21690560-Young Adult
|
| pubmed:year |
2011
|
| pubmed:articleTitle |
Trends in allogeneic stem cell transplantation for multiple myeloma: a CIBMTR analysis.
|
| pubmed:affiliation |
Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN, USA.
|
| pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, U.S. Gov't, Non-P.H.S.,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|